GlassScriptPhysician profile
Dean L Kellogg
NPI 1497119739
$1,561.84
in general payments reported to CMS, 2019-2025
11 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $852 · 2023: $329 · 2024: $140 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613 · Education: $96.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.73 |
| Education | $96.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $625.77 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Fujifilm Sonosite, INC. | $447.52 | 2022 | |
| Insmed, INC. | $173.93 | 2022-2023 | Arikayce |
| United Therapeutics Corporation | $92.21 | 2023-2024 | Tyvaso |
| Exthera Medical Corporation | $89.60 | 2022 | |
| Abbvie INC. | $45.15 | 2024 | |
| Janssen Pharmaceuticals, INC | $28.68 | 2022 | |
| Alcresta Therapeutics, INC. | $28.61 | 2025 | Relizorb |
| Shionogi INC | $17.55 | 2023 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $12.82 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.